                         SEQUENCE LISTING

<110>  University of Tartu
 
<120>  CELL PENETRATING PEPTIDES

<130>  TAR-P2460PCT

<160>  21    

<170>  PatentIn version 3.5

<210>  1
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Cell penetrating amino acid sequence; NF55


<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa = Orn; the peptide continues from the side chain amino group 
       and not from the alpha-amino group

<400>  1

Ala Gly Tyr Leu Leu Gly Xaa Ile Asn Leu Lys Ala Leu Ala Ala Leu 
1               5                   10                  15      


Ala Lys Ala Ile Leu 
            20      


<210>  2
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Cell penetrating amino acid sequence; NF71, N712, NF713, NF717


<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa = Orn; the peptide continues from the side chain amino group 
       and not from the alpha-amino group

<400>  2

His His Tyr His His Gly Xaa Ile Leu Leu Lys Ala Leu Lys Ala Leu 
1               5                   10                  15      


Ala Lys Ala Ile Leu 
            20      


<210>  3
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Cell penetrating amino acid sequence; NF70, NF703, NF702, NF701, 
       NF700, NF711


<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Xaa = Orn; the peptide continues from the side chain amino group 
       and not from the alpha-amino group

<400>  3

His His His His Tyr His His Gly Xaa Ile Leu Leu Lys Ala Leu Lys 
1               5                   10                  15      


Ala Leu Ala Lys Ala Ile Leu 
            20              


<210>  4
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Cell penetrating amino acid sequence; NF704, NF705, NF706


<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa = Orn; the peptide continues from the side chain amino group 
       and not from the alpha-amino group

<400>  4

His His His His His His Gly Xaa Ile Leu Leu Lys Ala Leu Lys Ala 
1               5                   10                  15      


Leu Ala Lys Ala Ile Leu 
            20          


<210>  5
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Cell penetrating amino acid sequence; NF72, NF721, NF722


<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa = Orn; the peptide continues from the side chain amino group 
       and not from the alpha-amino group

<400>  5

His His His His His His Tyr His His Gly Xaa Ile Leu Leu Lys Ala 
1               5                   10                  15      


Leu Lys Ala Leu Ala Lys Ala Ile Leu 
            20                  25  


<210>  6
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  General formula of the cell penentrating amino acid sequence of 
       the invention


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa = Orn; the peptide continues from the side chain amino group 
       and not from the alpha-amino group

<400>  6

His Tyr His His Gly Xaa Ile Leu Leu Lys Ala Leu Lys Ala Leu Ala 
1               5                   10                  15      


Lys Ala Ile Leu 
            20  


<210>  7
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  siRNA sense strand against luc2

<400>  7
ggacgaggac gagcacuuct t                                                 21


<210>  8
<211>  21
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  siRNA antisense strand against luc2

<400>  8
gaagugcucg uccucguccu u                                                 21


<210>  9
<211>  21
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  siRNA sense strand against GFP

<400>  9
ggcuacgucc aggagcgcac c                                                 21


<210>  10
<211>  21
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  siRNA antisense strand against GFP

<400>  10
ugcgcuccug gacguagccu u                                                 21


<210>  11
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Mus blood coagulation factor VII forward PCR primer

<400>  11
acaagtctta cgtctgcttc t                                                 21


<210>  12
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Mus blood coagulation factor VII reverse PCR primer

<400>  12
cacagatcag ctgctcattc t                                                 21


<210>  13
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Mus Actin beta forward PCR primer

<400>  13
ccacacccgc caccagttcg                                                   20


<210>  14
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Mus Actin beta reverse PCR primer

<400>  14
tacagcccgg ggagcatcgt                                                   20


<210>  15
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Cell penetrating amino acid sequence; NF707, NF708, NF709


<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa = Orn; the peptide continues from the side chain amino group 
       and not from the alpha amino group

<400>  15

His His His His His His Tyr Leu Leu Gly Xaa Ile Leu Leu Lys Ala 
1               5                   10                  15      


Leu Lys Ala Leu Ala Lys Ala Ile Leu 
            20                  25  


<210>  16
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Cell penetrating amino acid sequence of Figure 12, NF714


<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa = Orn; the peptide continues from the side chain amino group 
       and not from the alpha-amino group

<400>  16

His His Tyr His His Gly Xaa Ile Asn Leu Lys Ala Leu Lys Ala Leu 
1               5                   10                  15      


Ala Lys Ala Ile Leu 
            20      


<210>  17
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Cell penetrating amino acid sequence of Figure 12, NF73


<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa = Orn; the peptide continues from the side chain amino group 
       and not from the alpha-amino group

<400>  17

Ala Gly Tyr Leu Leu Gly Xaa Ile His Leu Lys Ala His Lys Ala His 
1               5                   10                  15      


Ala Lys Ala His Leu 
            20      


<210>  18
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Cell penetrating amino acid sequence of Figure 12, NF74


<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa = Orn; the peptide continues from the side chain amino group 
       and not from the alpha-amino group

<400>  18

Ala Gly Tyr Leu Leu Gly Xaa Ile Leu His Lys Ala His His Lys Leu 
1               5                   10                  15      


His Lys Ala Ile Leu 
            20      


<210>  19
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Cell penetrating amino acid sequence of the invention; NF725, 
       NF726, NF727


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa = Orn; the peptide continues from the side chain amino group 
       and not from the alpha-amino group

<400>  19

His Tyr His His Gly Xaa Ile Leu Leu Lys Ala Leu Lys Ala Leu Ala 
1               5                   10                  15      


Lys Ala Ile Leu 
            20  


<210>  20
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Cell penetrating amino acid sequence of the invention; NF715, 
       NF716, NF718


<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa = Orn; the peptide continues from the side chain amino group 
       and not from the alpha-amino group

<400>  20

His His His Tyr His His Gly Xaa Ile Leu Leu Lys Ala Leu Lys Ala 
1               5                   10                  15      


Leu Ala Lys Ala Ile Leu 
            20          


<210>  21
<211>  24
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Cell penetrating amino acid sequence of the invention; NF719, 
       NF723, NF724


<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa = Orn; the peptide continues from the side chain amino group 
       and not from the alpha-amino group

<400>  21

His His His His His Tyr His His Gly Xaa Ile Leu Leu Lys Ala Leu 
1               5                   10                  15      


Lys Ala Leu Ala Lys Ala Ile Leu 
            20                  


